首创的双效血管紧张素受体-脑啡肽酶抑制药沙库必曲/缬沙坦概述  

Overview on an Originate Angiotensin Ⅱ Receptor-Neprilysin Inhibitor with Double Effect: Sacubitril / Valsartan

作　　者：李欣[1] 雷兵团[1] 李超[1] 

机构地区：[1]河北开滦总医院药剂科,河北唐山063000

出　　处：《中国药师》2016年第6期1167-1169,共3页China Pharmacist

摘　　要：首创的双效血管紧张素受体-脑啡肽酶抑制药沙库必曲/缬沙坦,全新的独特作用模式,在增强心脏的保护性神经内分泌系统的同时,抑制肾素-血管紧张素-醛固酮系统,是首个也是唯一一个在临床试验中证实,疗效显著超越标准治疗药物依那普利的药物,而且表现出更高的安全性,为治疗心脏衰竭、降低心血管死亡和心脏衰竭住院风险提供了新的更安全的治疗模式。An originate angiotensin Ⅱ receptor-neprilysin inhibitor sacubitril/valsartan with double effect and a new active mode can not only promote the protection of heart and neuroendocrine system, but also inhibit renin-angiotensin-aldosterone system. Sacubi- tri/fvalsartan is the first and only one conformed by clinical trials with better efficacy when compared with standard therapy drug enala- pril, and its safety is higher as well. Sacubitril-valsartan represents a promising new treatment option for heart failure patients with low- ered risk of cardiovascular death and hospitalization for heart failure.

关 键 词：脑啡肽酶抑制药 血管紧张素Ⅱ受体阻断药 心脏衰竭 沙库必曲/缬沙坦 

分 类 号：R972.6[医药卫生—药品]